Open AccessAcute generalised exanthematous pustulosis: An update
Author(s) -
Abhishek De,
Sudip Das,
Aarti Sarda,
Dayamay Pal,
Projna Biswas
Publication year - 2018
Publication title -
indian journal of dermatology/indian journal of dermatology
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 0.395
H-Index - 36
eISSN - 1998-3611
pISSN - 0019-5154
DOI - 10.4103/ijd.ijd_581_17
Subject(s) - medicine , acute generalized exanthematous pustulosis , dermatology , antibiotics , incidence (geometry) , drug reaction , pustulosis , drug , adverse drug reaction , surgery , pharmacology , physics , osteomyelitis , microbiology and biotechnology , osteitis , optics , biology
Acute generalised exanthematous pustulosis (AGEP) is a severe cutaneous adverse reaction and is attributed to drugs in more than 90% of cases. It is a rare disease, with an estimated incidence of 1-5 patients per million per year. The clinical manifestations characterised by the rapid development of sterile pustular lesions, fever and leucocytosis. Number of drugs has been reported to be associated with AGEP, most common being the antibiotics. Histopathologically there is intraepidermal pustules and papillary dermal oedema with neutrophilic and eosinophilic infiltrations. Systemic involvement can be present in more severe cases. Early diagnosis with withdrawal of the causative drug is the most important step in the management. Treatment includes supportive care, prevention of antibiotics and use of a potent topical steroid.